CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

Table 2 Predictive performance (and 95% confidence interval) of the DLDA30 predictor in patients treated with preoperative chemotherapy

	Breast tumors of any phenotype	HER-2-positive breast tumors
Performance metrics	Validation cohort T/FAC^a n = 51	Present study cohort Trastuzumab + T/FEC n = 45	Subset of validation cohort T/FAC^a n = 30
Area under the curve	0.877 (0.066)	0.565 (0.089)	0.81 (0.092)
Overall accuracy	0.76 (0.62–0.87)	0.51 (0.36–0.66)	0.67 (0.47–0.83)
Sensitivity	0.92 (0.64–1.00)	0.52 (0.33–0.71)	0.90 (0.56–1.00)
Specificity	0.71 (0.54–0.85)	0.50 (0.25–0.75)	0.55 (0.32–0.77)
Positive predictive value	0.52 (0.31–0.73)	0.65 (0.43–0.84)	0.50 (0.26–0.74)
Negative predictive value	0.96 (0.82–1.00)	0.36 (0.17–0.59)	0.92 (0.62–1.00)

^aHess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, et al. [17]. T/FAC, paclitaxel followed by 5-fluorouracil, doxorubicin, and cyclophosphamide; T/FEC, paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide.

ISSN: 1465-542X